Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer

Medical Oncology

Volumn 25, Issue 3, 2008, Pages 279-283

  Acar, Ayla ^a   Onan, Anil ^a   Coskun, Ugur ^b   Uner, Aytug ^a   Bagriacik, Umit ^a   Atalay, Funda ^c   Unsal, Diclehan Kilic ^a   Guner, Haldun ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b Ankara Onkoloji Hospital ^*  (Turkey)

^c Ankara Onkoloji   (Turkey)

Author keywords

Gelatinase A; Matrylisin; MMPs; Ovarian tumor; Prognosis; Serum marker

Indexed keywords

GELATINASE A; MATRILYSIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGIC DISEASE; HUMAN; LYMPH NODE METASTASIS; OVARY CARCINOMA; OVARY TUMOR; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ADOLESCENT; BLOOD; CANCER STAGING; METASTASIS; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 58149250998     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-9031-1     Document Type: Article

References (31)

1. A Westerlund M Apaja-Sarkkinen M Höyhtya U Puistola T Turpeenniemi-Hujanen 1999 Gelatinase A-immunoreactive protein in ovarian lesions-prosnoctic value in epithelial ovarian cancer Gynecol Oncol 5 91 8
2. E Lengyel B Schmalfeldt E Konik K Späthe K Härting A Fenn U Berger R Fridman M Schmitt D Preehtel W Kuhn 2001 Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer Gynecol Oncol 82 291 8
3. X Wu H Li L Kang L Li W Wang B Shan 2002 Activated matrix metalloproteinase-2- a potential marker of prognosis for epithelial ovarian cancer Gynecol Oncol 84 1 126 34
4. J Westermarck VM Kahari 1999 Regulation of matrix metalloproteinase expression in tumor invasion FASEB J 13 781 92
5. MD Sternlicht Z Werb 2001 How matrix metalloproteinases regulate cell behavior Annu Rev Cell Dev Biol 17 463 516
6. SM Ranuncolo E Armanasco C Cresta E Bal De Kier Joffe L Puricelli 2003 Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients Int J Cancer 106 745 51
7. S Kermorgant T Aparicio V Dessirier MJ Lewin T Lehy 2001 Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement Carcinogenesis 22 1035 42
8. T Shiomi Y Okada 2003 MT1-MMP and MMP-7 in invasion and metastasis of human cancers Cancer Metastasis Rev 22 145 52
9. FQ Wang J So S Reierstad DA Fishman 2005 Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase Int J Cancer 114 1 19 31
10. Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Marmol M, Gallardo E, Maria Auge J, Longaron R, Martinez-Fernandez A, Molina R, Castells A, Gascon P. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 2007 May 8; [Epub ahead of print].
11. K Gohji N Fujimoto T Komiyama A Fujii J Ohkawa S Kamidono M Nakajima 1996 Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma Cancer 78 2379 87
12. SM Sheen-Chen HS Chen HL Eng CC Sheen WJ Chen 2001 Serum levels of matrix metalloproteinase 2 in patients with breast cancer Cancer Lett 173 79 82
13. SC Liu SF Yang KT Yeh CM Yeh HL Chiou CY Lee MC Chou YS Hsieh 2006 Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer Clin Chim Acta 371 92 6
14. A Oberg M Hoyhtya B Tavelin R Stenling G Lindmark 2000 Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer Anticancer Res 20 1085 91
15. MM Pacheco M Mourao EB Mantovani IN Nishimoto MM Brentani 1998 Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations Clin Exp Metastasis 16 577 85
16. N Kawano H Osawa T Ito Y Nagashima F Hirahara Y Inayama Y Nakatani S Kimura H Kitajima N Koshikawa K Miyazaki H Kitamura 1997 Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study Hum Pathol 28 613 22
17. U Coskun D Yamac O Gulbahar B Sancak N Karaman S Ozkan 2007 Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response? Neoplasma 54 348 52
18. F.I.G.O. News. Int J Gynecol Obstet 1989;28:189-93.
19. J Nikkola P Vihinen MS Vuoristo P Kellokumpu-Lehtinen VM Kahari S Pyrhonen 2005 High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma Clin Cancer Res 11 5158 66
20. LA Liotta PS Steeg WG Stetler-Stevenson 1991 Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation Cell 64 2 327 36
21. NB Liabakk I Talbot RA Smith K Wilkinson F Balkwill 1996 Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer Cancer Res 56 190 6
22. I Shima Y Sasaguri J Kusukawa H Yamana H Fujita T Kakegawa M Morimatsu 1992 Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study Cancer 70 2747 53
23. SB Somiari RI Somiari CM Heckman CH Olsen RM Jordan SJ Russell CD Shriver 2006 Circulating MMP2 and MMP9 in breast cancer-potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories Int J Cancer 119 1403 11
24. H Sasaki H Yukiue Y Kobayashi M Kaji M Kiriyama I Fukai Y Yamakawa Y Fujii 2002 Elevated serum pro-MMP2 levels in patients with stage IV thymoma Surg Today 32 482 6
25. SM Sillanpaa MA Anttila KA Voutilainen KM Ropponen RK Sironen SV Saarikoski VM Kosma 2006 Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression Int J Cancer 119 1792 9
26. GG Garzetti A Ciavattini G Lucarini G Goteri M de e Nictolis S Garbisa L Masiero C Romanini B Graziella 1995 Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications Anticancer Res 15 2799 804
27. Demeter A, Sziller I, Csapo Z, Olah J, Keszler G, Jeney A, Papp Z, Staub M. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer Anticancer Res 2005;25:2885-9.
28. J Komorowski Z Pasieka J Jankiewicz-Wika H Stepien 2002 Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer Thyroid 12 655 62
29. ZS Galis GK Sukhova MW Lark P Libby 1994 Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques J Clin Invest ;94 2493 503
30. MH Tayebjee GY Lip RJ MacFadyen 2005 Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance Curr Med Chem 12 917 25
31. KC Lewandowski J Komorowski CJ O'Callaghan BK Tan J Chen GM Prelevic HS Randeva 2006 Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome J Clin Endocrinol Metab 91 1173 7